Stock Scorecard
Stock Summary for Fennec Pharmaceuticals Inc (FENC) - $7.62 as of 12/17/2025 10:44:21 AM EST
Total Score
9 out of 30
Safety Score
28 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for FENC
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for FENC
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for FENC
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for FENC
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for FENC (28 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for FENC
Financial Details for FENC
Company Overview |
|
|---|---|
| Ticker | FENC |
| Company Name | Fennec Pharmaceuticals Inc |
| Country | USA |
| Description | Fennec Pharmaceuticals Inc. is a cutting-edge biopharmaceutical company headquartered in Research Triangle Park, North Carolina, dedicated to developing innovative therapies for cancer with a focus on pediatric patients. The company's lead product, Pedmark, is a novel treatment aimed at preventing chemotherapy-induced ototoxicity, representing a significant advancement in supportive care for young cancer patients. With a commitment to enhancing the quality of life for its patients, Fennec is well-positioned to address critical unmet medical needs in oncology, both domestically and internationally, thereby establishing itself as a key player in the biopharmaceutical sector. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 7.62 |
| Price 4 Years Ago | 4.40 |
| Last Day Price Updated | 12/17/2025 10:44:21 AM EST |
| Last Day Volume | 152,734 |
| Average Daily Volume | 172,822 |
| 52-Week High | 9.92 |
| 52-Week Low | 4.68 |
| Last Price to 52 Week Low | 62.82% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 23.33 |
| Sector PE | 104.08 |
| 5-Year Average PE | -18.14 |
| Free Cash Flow Ratio | 11.91 |
| Industry Free Cash Flow Ratio | 15.84 |
| Sector Free Cash Flow Ratio | 23.00 |
| Current Ratio Most Recent Quarter | 4.69 |
| Total Cash Per Share | 0.64 |
| Book Value Per Share Most Recent Quarter | -0.16 |
| Price to Book Ratio | 57.93 |
| Industry Price to Book Ratio | 47.50 |
| Sector Price to Book Ratio | 21.07 |
| Price to Sales Ratio Twelve Trailing Months | 6.65 |
| Industry Price to Sales Ratio Twelve Trailing Months | 23.27 |
| Sector Price to Sales Ratio Twelve Trailing Months | 17.16 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 34,153,500 |
| Market Capitalization | 260,249,670 |
| Institutional Ownership | 46.90% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 1.98% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 97.28% |
| Reported EPS 12 Trailing Months | -0.26 |
| Reported EPS Past Year | -0.17 |
| Reported EPS Prior Year | 0.00 |
| Net Income Twelve Trailing Months | -6,940,000 |
| Net Income Past Year | -436,000 |
| Net Income Prior Year | -16,045,000 |
| Quarterly Revenue Growth YOY | 78.70% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | -1.52% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 21,925,606 |
| Total Cash Past Year | 26,634,000 |
| Total Cash Prior Year | 13,269,000 |
| Net Cash Position Most Recent Quarter | 2,548,606 |
| Net Cash Position Past Year | 7,296,000 |
| Long Term Debt Past Year | 19,338,000 |
| Long Term Debt Prior Year | 30,931,000 |
| Total Debt Most Recent Quarter | 19,377,000 |
| Equity to Debt Ratio Past Year | -0.44 |
| Equity to Debt Ratio Most Recent Quarter | -0.30 |
| Total Stockholder Equity Past Year | -5,872,000 |
| Total Stockholder Equity Prior Year | -11,622,000 |
| Total Stockholder Equity Most Recent Quarter | -4,487,621 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -7,985,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.23 |
| Free Cash Flow Past Year | 26,980,000 |
| Free Cash Flow Prior Year | -17,143,003 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 0.75 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 7.71 |
| 200-Day SMA | 7.58 |
System |
|
| Modified | 12/15/2025 11:01:25 PM EST |